Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eli Lilly Completes AtaiBeckley Acquisition | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eli Lilly Completes AtaiBeckley Acquisition

Deal adds BPL-003, AtaiBeckley’s lead program for treatment-resistant depression.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Editor’s Take: Lilly continues to expand its pipeline through key acquisitions. Other acquisitions this year include Ajax Therapeutics, Centessa Pharmaceuticals and Ventyx Biosciences.

Eli Lilly and Company completed its previously announced acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions.

The deal included BPL-003, AtaiBeckley’s lead investigational program for treatment-resistant depression.

“Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief,” said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. “AtaiBeckley’s neuroplastogens have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing. It’s the innovation this field needs, and we are committed to advancing them for patients who need more options.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics